Share

    • First human dosed with cellular reprogramming drug in longevity trial

    By The Washington Times June 16, 2026
    A Boston biotech company has administered what researchers are describing as the first human dose of a cellular rejuvenation drug, a milestone in the effort to treat age-related disease at the epigenetic level.
    First human dosed with cellular reprogramming drug in longevity trial

    First human dosed with cellular reprogramming drug in longevity trial Researchers have administered the first human dose of a cellular rejuvenation drug developed by a Boston biotech company. This marks a significant milestone in the quest to treat age-related diseases. The drug targets the epigenetic level, aiming to reverse cellular aging.

    • A Boston biotech company has administered the first human dose of a cellular rejuvenation drug.
    • This is described as a milestone in treating age-related disease.
    • The treatment targets disease at the epigenetic level.
    Write a comment